This skill defines the treatment goals for patients with overt Cushing's syndrome, focusing on normalizing cortisol levels or action to eliminate symptoms and treat comorbidities. Use when a clinician asks about treatment objectives for a newly diagnosed overt Cushing's syndrome patient; triggers include "overt CS," "treatment goals for overt Cushing's," and "normalize cortisol in overt CS."
中文简介正在准备中。当前显示原文说明。
dromlakhani/MD2SKILL☆ 142026年10月28日 更新
This skill recommends unilateral resection by an experienced adrenal surgeon for all cases of benign unilateral disease causing Cushing's syndrome. Trigger when a CS patient has a unilateral adrenal lesion confirmed benign via imaging and biochemical assessment.
中文简介正在准备中。当前显示原文说明。
dromlakhani/MD2SKILL☆ 142026年10月28日 更新
This skill recommends urgent treatment (within 24–72 hours) of hypercortisolism when life‑threatening complications of Cushing's syndrome such as infection, pulmonary thromboembolism, cardiovascular events, or acute psychosis are present. Trigger phrases include sepsis, PE, chest pain with hemodynamic instability, new‑onset psychosis, or delirium in a patient with known or suspected Cushing's.
中文简介正在准备中。当前显示原文说明。
dromlakhani/MD2SKILL☆ 142026年10月28日 更新
This skill suggests medical therapy to block aberrant hormone receptors for bilateral macronodular adrenal hyperplasia (BMAH) when surgery is not preferred or feasible. Consider this approach in patients with confirmed BMAH and evidence of aberrant hormone receptor expression (e.g., GIP, LH/hCG, serotonin) driving cortisol excess.
中文简介正在准备中。当前显示原文说明。
dromlakhani/MD2SKILL☆ 142026年10月28日 更新
Determines when adrenal venous sampling (AVS) is indicated for functional subtyping of primary aldosteronism (PA) when surgical treatment is feasible and desired by the patient. Triggered when a clinician confirms PA diagnosis and asks 'Do I need AVS for subtyping?' or evaluates surgical candidacy.
中文简介正在准备中。当前显示原文说明。
dromlakhani/MD2SKILL☆ 142026年10月28日 更新
This skill suggests using denosumab rather than an intravenous bisphosphonate for adults with hypercalcemia of malignancy. It is triggered when a clinician questions which antiresorptive to choose first or seeks guidance on drug selection for HCM.
中文简介正在准备中。当前显示原文说明。
dromlakhani/MD2SKILL☆ 142026年10月28日 更新
Calculates salmon calcitonin dose based on patient weight for rapid calcium lowering in hypercalcemia of malignancy. Triggered when a clinician considers rapid calcium lowering and asks about weight‑based calcitonin dosing.
中文简介正在准备中。当前显示原文说明。
dromlakhani/MD2SKILL☆ 142026年10月28日 更新
Determines whether to recommend unilateral laparoscopic adrenalectomy or medical therapy with a mineralocorticoid receptor antagonist for patients with confirmed unilateral PA (aldosterone-producing adenoma or unilateral adrenal hyperplasia). Triggered when discussing treatment options after confirming unilateral PA in a hypertensive patient with hypokalemia or resistant hypertension.
中文简介正在准备中。当前显示原文说明。
dromlakhani/MD2SKILL☆ 142026年10月28日 更新
Recommends switching specific anti-hypertensive medications to reduce false-positive and false-negative screening results for primary aldosteronism. Triggered when a clinician notes 'The patient is on ACE inhibitors/ARBs' or suspects medication interference with screening results.
中文简介正在准备中。当前显示原文说明。
dromlakhani/MD2SKILL☆ 142026年10月28日 更新
Recommends adding intravenous bisphosphonate or denosumab in adults with hypercalcemia of malignancy due to tumors with high calcitriol levels (e.g., lymphoma) who remain severe or symptomatic despite glucocorticoid therapy. Use when managing lymphoma‑related HCM on steroids and considering escalation of antiresorptive therapy.
中文简介正在准备中。当前显示原文说明。
dromlakhani/MD2SKILL☆ 142026年10月28日 更新
This skill suggests treatment with either a calcimimetic or an intravenous bisphosphonate/denosumab for hypercalcemia due to parathyroid carcinoma. Triggered when a clinician diagnoses parathyroid carcinoma-associated hypercalcemia of malignancy and inquires about initial medical management options.
中文简介正在准备中。当前显示原文说明。
dromlakhani/MD2SKILL☆ 142026年10月28日 更新
Recommends adding intravenous bisphosphonate or denosumab when hypercalcemia due to parathyroid carcinoma is not adequately controlled with a calcimimetic. Consider this adjunct when a clinician notes persistent HCM despite calcimimetic therapy and asks about next-step therapy.
中文简介正在准备中。当前显示原文说明。
dromlakhani/MD2SKILL☆ 142026年10月28日 更新
Determines whether to recommend adrenalectomy or mineralocorticoid receptor antagonists for primary aldosteronism based on PA subtype and patient/surgical factors. Triggered after subtype confirmation when clinicians ask “Should this patient have surgery or medical treatment?” or discuss treatment options with the patient.
中文简介正在准备中。当前显示原文说明。
dromlakhani/MD2SKILL☆ 142026年10月28日 更新
Identifies safe antihypertensive options for hypertensive disorders in pregnancy applicable to PA patients, with gestational age restrictions. Triggers include when managing hypertension in a pregnant or pregnancy-planning PA patient and asking 'What BP meds are safe?' or reviewing medications.
中文简介正在准备中。当前显示原文说明。
dromlakhani/MD2SKILL☆ 142026年10月28日 更新
Suggests considering mineralocorticoid receptor antagonists when benefits outweigh risks in pregnant or preconception PA patients with uncontrolled hypertension and hypokalemia. Triggered when standard therapy fails and clinicians ask 'Should I consider MRAs despite pregnancy?' or when assessing risk‑benefit of MRA use.
中文简介正在准备中。当前显示原文说明。
dromlakhani/MD2SKILL☆ 142026年10月28日 更新
Provides a checklist of five evidence-based measures to enhance the technical success of adrenal venous sampling procedures. Triggers include when preparing for AVS and asking 'How can I maximize success rate?' or troubleshooting failed attempts.
中文简介正在准备中。当前显示原文说明。
dromlakhani/MD2SKILL☆ 142026年10月28日 更新
Recommends potassium supplementation for hypokalemia management in PA patients who are pregnant or planning pregnancy. Triggered when a pregnant PA patient presents with low serum potassium and asks 'How should I treat hypokalemia?' or when electrolytes are reviewed.
中文简介正在准备中。当前显示原文说明。
dromlakhani/MD2SKILL☆ 142026年10月28日 更新
Provides guidance on acceptable blood sampling conditions for primary aldosteronism screening when ideal early‑morning supine fasting conditions cannot be met. Triggers include when a clinician says “The patient wasn’t fasting/supine” or questions whether non‑ideal sampling affects screening validity.
中文简介正在准备中。当前显示原文说明。
dromlakhani/MD2SKILL☆ 142026年10月28日 更新
Guides choice among spironolactone, eplerenone, and esaxerenone for primary aldosteronism based on comparative efficacy, safety, and patient-specific factors. Triggers include when initiating MRA therapy and asking 'Which MRA should I prescribe?' or considering switching agents due to adverse effects, cost, or need for potassium supplementation.
中文简介正在准备中。当前显示原文说明。
dromlakhani/MD2SKILL☆ 142026年10月28日 更新
Recommends mineralocorticoid receptor antagonists for all primary aldosteronism patients to prevent target organ damage, irrespective of blood pressure control or serum potassium levels. Triggered when a clinician encounters a PA patient with well‑controlled BP and normal K and wonders, 'Do I still need to treat with MRA?' or considers stopping therapy.
中文简介正在准备中。当前显示原文说明。
dromlakhani/MD2SKILL☆ 142026年10月28日 更新
This skill recommends computed tomography (CT) as the initial imaging modality for primary aldosteronism (PA) evaluation in Japan, citing its accessibility and comparable performance to MRI. It is triggered when a clinician orders imaging for suspected PA and asks 'What imaging should I start with?' or seeks a cost-effective initial evaluation.
中文简介正在准备中。当前显示原文说明。
dromlakhani/MD2SKILL☆ 142026年10月28日 更新
Identifies young patients with classic primary aldosteronism features who may proceed directly to unilateral adrenalectomy without adrenal venous sampling based on high probability of unilateral disease. Triggered when a clinician sees a patient <35 years with hypokalemia, unilateral adrenal tumor on CT, and high plasma aldosterone concentration and asks whether AVS can be bypassed.
中文简介正在准备中。当前显示原文说明。
dromlakhani/MD2SKILL☆ 142026年10月28日 更新
This skill provides criteria to distinguish unilateral from bilateral primary aldosteronism using adrenal venous sampling results, including lateralization index, contralateral ratio, and clinical factors. It is triggered after AVS when clinicians analyze results and ask 'Is this unilateral or bilateral PA?' or need to guide treatment decisions.
中文简介正在准备中。当前显示原文说明。
dromlakhani/MD2SKILL☆ 142026年10月28日 更新
Determines successful catheterization in adrenal venous sampling by applying selectivity index cut‑offs with and without ACTH stimulation. Triggered during AVS when measuring cortisol levels and asking “Is the catheter properly positioned?” or when reviewing results for technical adequacy.
中文简介正在准备中。当前显示原文说明。
dromlakhani/MD2SKILL☆ 142026年10月28日 更新